Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

by Bin-Chi Liao, MD, Wei-Hsun Hsu, MD, Jih-Hsiang Lee, MD, Ching-Yao Yang, MD, PhD, Tzu-Hsiu Tsai, MD, PhD, Wei-Yu Liao, MD, PhD, Chao-Chi Ho, MD, PhD, Chia-Chi Lin, MD, PhD, Jin-Yuan Shih, MD, PhD, Chong-Jen Yu, MD, PhD, Ross A. Soo, M.B.B.S., James Chih-Hsin Yang, MD, PhD
Published 2021-01-01

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

by Keunchil Park, MD, PhD, Daniel Shao Weng Tan, BSc, M.B.B.S., MRCP, Wu-Chou Su, MD, Byoung Chul Cho, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Chin-Chou Wang, MD, MS, Takashi Seto, MD, Dennis Chin-Lun Huang, MD, Helen Hayoun Jung, BS, RPh, Ming-Chi Hsu, PhD, Thomas Bogenrieder, MD, PhD, Chia-Chi Lin, MD, PhD
Published 2021-09-01